Fat embolism syndrome epidemiology and demographics: Difference between revisions

	Fat embolism syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Fat embolism syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Fat embolism syndrome epidemiology and demographics On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Fat embolism syndrome epidemiology and demographics All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Fat embolism syndrome epidemiology and demographics
CDC on Fat embolism syndrome epidemiology and demographics
Fat embolism syndrome epidemiology and demographics in the news
Blogs on Fat embolism syndrome epidemiology and demographics
Directions to Hospitals Treating Fat embolism syndrome
Risk calculators and risk factors for Fat embolism syndrome epidemiology and demographics

Revision as of 15:00, 6 March 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Feham Tariq, MD [2]

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.

The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
The prevalence of [disease/malignancy] is estimated to be [number] cases annually.

In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
The case-fatality rate/mortality rate of [disease name] is approximately [number range].

There is no racial predilection to [disease name].
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

[Disease name] affects men and women equally.
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

@@ Line 22: / Line 22: @@
 ===Age===
-*Patients of all age groups may develop [disease name].
+*The incidence of fat embolism syndrome increases with age.
-*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
+*Fat embolism syndrome commonly affects individuals 10-40 years of age.
-*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
-*[Chronic disease name] is usually first diagnosed among [age group].
-*[Acute disease name] commonly affects [age group].
 ===Race===